345 PARK AVENUE SOUTH, NEW YORK, NY
Financial Results, Other Events
Annual Report to Security Holders
Dr. Laura Sepp-Lorenzino Appointed to Lexeo Therapeutics Board
Investor Presentation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Jose Manuel Otero Appointed Chief Operating Officer at Lexeo Therapeutics
Reports Third Quarter 2025 Financial Results and Operational Highlights
Q1
FY 2025
Q3
Q2
Amended Quarterly Report
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Free Writing Prospectus